Artivion Continues Building Toward Bigger And Better Things [Seeking Alpha]
Artivion, Inc. (AORT)
Company Research
Source: Seeking Alpha
Recent clinical updates for the AMDS prosthesis reinforce its safety and efficacy, supporting further adoption and de-risking full commercialization. I expect double-digit long-term revenue growth, expanding EBITDA margins, and a fair value in the high-$50s, justifying a bullish stance. Upcoming catalysts include full FDA approval for AMDS and Nexus approval and launch in 2026. benote/iStock via Getty Images A lot of the value I see at Artivion ( AORT ) still lives in the clinic and is dependent upon clinical results, FDA approvals, and successful commercialization, but the company does continue to execute well, building confidence in the longer-term execution story. This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation fo
Show less
Read more
Impact Snapshot
Event Time:
AORT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AORT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AORT alerts
High impacting Artivion, Inc. news events
Weekly update
A roundup of the hottest topics
AORT
News
- 1 Profitable Stock with Exciting Potential and 2 Facing Headwinds [Yahoo! Finance]Yahoo! Finance
- Assessing Artivion (AORT) Valuation After Strong Recent Returns And Ongoing Net Loss [Yahoo! Finance]Yahoo! Finance
- 1 Healthcare Stock on Our Watchlist and 2 We Ignore [Yahoo! Finance]Yahoo! Finance
- 1 Safe-and-Steady Stock on Our Watchlist and 2 We Avoid [Yahoo! Finance]Yahoo! Finance
- Artivion (NYSE:AORT) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=AORT&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> froMarketBeat
AORT
Earnings
- 11/6/25 - Beat
AORT
Sec Filings
- 12/17/25 - Form 4
- 12/17/25 - Form 144
- 12/9/25 - Form 4
- AORT's page on the SEC website